retatrutide trial Seeking Differentiation Through a Triple Mechanism" Eli Lilly's Again Proves Efficacy in Trials, Raising Question of Whether It Can Overcome Side-Effect Limits and Reshape the Market Retatrutide Weight Loss Results:Trial Data

Retatrutide is a multi-receptor peptide agonist targeting GLP-1, GIP, and glucagon receptors, designed for advanced metabolic research

For years, the most powerful weight loss medications were weekly injections

Headaches and Injection Site Reactions Headaches and injection site reactions, including mild redness or irritation at the weekly injection site, were also documented in trial participants, though these were less commonly reported than gastrointestinal symptoms

In the control group, TCCs were lower, averaging $11,406, $11,882, and $13,012 for the same periods

Retatrutide is an investigational weight loss medication and is not FDA-approved at this time